Le Mans, France

Laurent Girodier


Average Co-Inventor Count = 13.0

ph-index = 2

Forward Citations = 12(Granted Patents)


Company Filing History:


Years Active: 2003-2004

Loading Chart...
2 patents (USPTO):Explore Patents

Title: Laurent Girodier: Innovator in Chemotherapy Solutions

Introduction

Laurent Girodier is a notable inventor based in Le Mans, France. He has made significant contributions to the field of chemotherapy through his innovative research and development of cephalotaxane derivatives. With a total of 2 patents, his work focuses on improving treatment options for patients.

Latest Patents

Girodier's latest patents include a groundbreaking process for the asymmetric hemisynthesis of harringtonines and their analogs. These alkaloids are crucial in chemotherapy, and his invention outlines a new general process that involves the direct esterification of a natural cephalotaxine with an acylating compound. This compound is characterized by a side chain precursor whose backbone and functionalization are entirely preformed. This innovative approach aims to enhance the efficacy of chemotherapy treatments.

Career Highlights

Throughout his career, Laurent Girodier has worked with prominent companies in the pharmaceutical industry, including Stragen Pharma and Oncopharm Corporation. His experience in these organizations has allowed him to collaborate on various projects aimed at advancing cancer treatment.

Collaborations

Girodier has collaborated with esteemed colleagues such as Jean-Pierre Robin and Julie Blanchard. Their combined expertise has contributed to the success of his innovative projects.

Conclusion

Laurent Girodier's contributions to the field of chemotherapy through his patents and collaborations highlight his commitment to improving cancer treatment. His innovative processes pave the way for more effective therapies, ultimately benefiting patients worldwide.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…